X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs STERLING BIOTECH - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES STERLING BIOTECH DIVIS LABORATORIES/
STERLING BIOTECH
 
P/E (TTM) x 34.5 -0.4 - View Chart
P/BV x 6.7 0.0 47,020.8% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DIVIS LABORATORIES   STERLING BIOTECH
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
STERLING BIOTECH
Dec-13
DIVIS LABORATORIES/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,14211 10,874.3%   
Low Rs5333 15,679.4%   
Sales per share (Unadj.) Rs146.626.8 546.8%  
Earnings per share (Unadj.) Rs33.0-15.0 -220.9%  
Cash flow per share (Unadj.) Rs38.4-5.5 -703.0%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.20-  
Book value per share (Unadj.) Rs222.854.9 406.0%  
Shares outstanding (eoy) m265.47267.87 99.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.70.3 2,203.5%   
Avg P/E ratio x25.3-0.5 -5,455.4%  
P/CF ratio (eoy) x21.8-1.3 -1,714.0%  
Price / Book Value ratio x3.80.1 2,967.7%  
Dividend payout %30.30-   
Avg Mkt Cap Rs m222,3181,862 11,941.7%   
No. of employees `00010.81.4 794.8%   
Total wages/salary Rs m4,561547 834.1%   
Avg. sales/employee Rs Th3,616.05,303.3 68.2%   
Avg. wages/employee Rs Th423.8403.8 104.9%   
Avg. net profit/employee Rs Th814.9-2,959.0 -27.5%   
INCOME DATA
Net Sales Rs m38,9157,181 541.9%  
Other income Rs m1,13443 2,662.9%   
Total revenues Rs m40,0497,223 554.4%   
Gross profit Rs m12,617947 1,332.5%  
Depreciation Rs m1,4252,543 56.0%   
Interest Rs m134,377 0.3%   
Profit before tax Rs m12,313-5,931 -207.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,543-1,924 -184.1%   
Profit after tax Rs m8,770-4,007 -218.9%  
Gross profit margin %32.413.2 245.9%  
Effective tax rate %28.832.4 88.7%   
Net profit margin %22.5-55.8 -40.4%  
BALANCE SHEET DATA
Current assets Rs m45,35114,335 316.4%   
Current liabilities Rs m6,50749,809 13.1%   
Net working cap to sales %99.8-494.0 -20.2%  
Current ratio x7.00.3 2,421.6%  
Inventory Days Days127403 31.4%  
Debtors Days Days95171 55.8%  
Net fixed assets Rs m21,16055,432 38.2%   
Share capital Rs m531268 198.2%   
"Free" reserves Rs m58,62513,935 420.7%   
Net worth Rs m59,15614,701 402.4%   
Long term debt Rs m09,478 0.0%   
Total assets Rs m67,83273,988 91.7%  
Interest coverage x926.8-0.4 -261,102.5%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.60.1 591.1%   
Return on assets %12.90.5 2,585.2%  
Return on equity %14.8-27.3 -54.4%  
Return on capital %20.8-6.4 -324.3%  
Exports to sales %025.9 0.0%   
Imports to sales %21.80.2 12,833.7%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs m8,48512 69,550.8%   
Fx inflow Rs m32,3591,860 1,739.9%   
Fx outflow Rs m9,04225 36,329.0%   
Net fx Rs m23,3171,835 1,270.7%   
CASH FLOW
From Operations Rs m7,7591,719 451.4%  
From Investments Rs m-4,783-3,148 151.9%  
From Financial Activity Rs m-3,1421,426 -220.3%  
Net Cashflow Rs m-166-3 4,882.4%  

Share Holding

Indian Promoters % 52.0 33.9 153.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 0.0 -  
FIIs % 19.0 9.9 191.9%  
ADR/GDR % 0.0 16.9 -  
Free float % 17.2 39.3 43.8%  
Shareholders   31,796 21,482 148.0%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   VENUS REMEDIES  SHASUN PHARMA  SANOFI INDIA  TTK HEALTHCARE  ORCHID PHARMA LTD  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Finish Flat; IT and Pharma Stocks Witness Selling(Closing)

Share markets in India ended their trading session on a flattish note. Sectoral indices ended on a mixed note with stocks in the IT sector and pharma sector witnessing most of the selling pressure.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Nov 14, 2018 03:35 PM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS